On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies.

A validated method for on-line solid-phase extraction coupled with high-performance liquid chromatography tandem mass spectrometry (SPE-HPLC-MS-MS) is described for the quantification of bromazepam in human plasma. The method involves a dilution of 300 muL of plasma with 100 muL of carbamazepine (2.5 ng/mL), used as internal standard, vortex-mixing, centrifugation, and injection of 100 muL of the supernate. The analytes were ionized using positive electrospray mass spectrometry then detected by multiple reaction monitoring (MRM). The m/z transitions 316-->182 (bromazepam) and 237-->194 (carbamazepine) were used for quantification. The calibration curve was linear from 1 ng/mL (limit of quantification) to 200 ng/mL. The retention times of bromazepam and carbamazepine were 2.6 and 3.2 minutes, respectively. The intraday and interday precisions were 3.43%-15.45% and 5.2%-17%, respectively. The intraday and interday accuracy was 94.00%-103.94%. This new automated method has been successfully applied in a bioequivalence study of 2 tablet formulations of 6 mg bromazepam: Lexotan(R) from Produtos Roche Químicos e Farmacêuticos SA, Rio de Janeiro, Brazil (reference) and test formulation from Laboratórios Biosintética Ltda, São Paulo, Brazil. Because the 90% CI of geometric mean ratios between reference and test were completely included in the 80%-125% interval, the 2 formulations were considered bioequivalent. The comparison of different experimental conditions for establishing a dissolution profile in vitro along with our bioavailability data further allowed us to propose rationally based experimental conditions for a dissolution test of bromazepam tablets, actually lacking a pharmacopeial monograph.

Comparison of CZE, MEKC, MEEKC and non-aqueous capillary electrophoresis for the determination of impurities in bromazepam.

The purpose of the present investigation was to develop a test for related substances in the benzodiazepine drug substance bromazepam based on capillary electrophoresis (CE). A final method for the determination of impurities in bromazepam is based on non-aqueous capillary electrophoresis (NACE). Five modes of capillary electrophoresis were investigated and compared for the said purpose. All the CE systems investigated make use of running buffers at low pH in order to protonate the analytes. A low pH of the running buffers was needed as the pK(a) values of benzodiazepines in general are in the range from 1.3 to 4.6. Dynamically coated capillaries were used to overcome the low electro-osmotic flow at low pH in the aqueous buffers investigated. CZE with and without dynamical coating of the internal surface of the fused capillaries was compared and also micellar electrokinetic chromatography (MEKC) as well as microemulsion electrokinetic chromatography (MEEKC) performed in dynamically coated capillaries were investigated. The NACE was chosen as the best technique as the low solubility of the benzodiazepines in water is easily overcome. The NACE system showed good selectivity and detectability for the substances investigated and the limit of quantitation for the impurities corresponded to 0.05% of the drug substance. Linearity was good.

Gas chromatographic determination of bromo and fluoro derivatives of benzodiazepine in human body fluids.

A rapid, sensitive and accurate method for the determination of bromazepam and flunitrazepam in plasma and urine using gas chromatography has been developed. Bromazepam was extracted with diethyl ether and flunitrazepam with hexane at pH 7. A nitrogen detector was used to determine bromazepam and an electron-capture detector was used for flunitrazepam.